BiotechTube

Adalimumab Injection + Thiopurine

ApprovedUNKNOWN
2 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Crohn Disease

Conditions

Crohn Disease, Inflammatory Bowel Diseases, Stricture; Bowel

Trial Timeline

Oct 9, 2017 → Sep 1, 2021

NCT ID
NCT03220841

About Adalimumab Injection + Thiopurine

Adalimumab Injection + Thiopurine is a approved stage product being developed by AbbVie for Crohn Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT03220841. Target conditions include Crohn Disease, Inflammatory Bowel Diseases, Stricture; Bowel.

What happened to similar drugs?

11 of 20 similar drugs in Crohn Disease were approved

Approved (11) Terminated (4) Active (9)
✅Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
✅MirikizumabEli LillyApproved
✅adalimumabAbbVieApproved
✅Infliximab 5 mg/kg + Infliximab 5 mg/kg every 6 weeks + Infliximab 7 mg/kg every 8 weeksMerckApproved
✅Infliximab + Prednisolone + AzathioprinePfizerApproved
✅Celebrex + placeboPfizerApproved
✅Cimzia + MesalamineUCBApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03220841ApprovedUNKNOWN

Competing Products

20 competing products in Crohn Disease

See all competitors
ProductCompanyStageHype Score
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
21
LY4395089 + Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)Eli LillyPhase 2
42
CT-P13 + RemicadeCelltrionPhase 3
40
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
39
Ustekinumab 45 mg + Ustekinumab 90 mgCelltrionPre-clinical
33
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
29
CT-P13 SC (Infliximab)CelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
CP-461Astellas PharmaPhase 2
35
UstekinumabSun PharmaceuticalPre-clinical
33
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
32
E6011 + PlaceboEisaiPhase 2
35
E6011 + PlaceboEisaiPhase 1
21
adalimumab + adalimumab + placeboEisaiPhase 2/3
38
adalimumabEisaiPhase 2/3
38
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
40
MirikizumabEli LillyPhase 3
47
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
47
Mirikizumab + PlaceboEli LillyPhase 2
35